EyePoint Pharmaceuticals (EYPT) Stock Overview
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EYPT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
EyePoint Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.08 |
| 52 Week High | US$14.91 |
| 52 Week Low | US$3.91 |
| Beta | 1.69 |
| 1 Month Change | -16.38% |
| 3 Month Change | 8.31% |
| 1 Year Change | -4.40% |
| 3 Year Change | 137.77% |
| 5 Year Change | 165.64% |
| Change since IPO | -64.94% |
Recent News & Updates
EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target
Oct 16EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Sep 06
Recent updates
EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target
Oct 16EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Sep 06After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
Jun 16Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth?
May 03
DURAVYU Phase III Trials Will Accelerate Market Entry
Expedited Phase III trial progress and robust patent protection could maximize long-term revenue and margin potential for DURAVYU.EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year
Mar 09EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Feb 26EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Jan 30EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
Dec 13EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16Shareholder Returns
| EYPT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.3% | 3.9% | -1.7% |
| 1Y | -4.4% | 6.8% | 12.3% |
Return vs Industry: EYPT underperformed the US Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: EYPT underperformed the US Market which returned 14.4% over the past year.
Price Volatility
| EYPT volatility | |
|---|---|
| EYPT Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EYPT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EYPT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 165 | Jay Duker | eyepointpharma.com |
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
EyePoint Pharmaceuticals, Inc. Fundamentals Summary
| EYPT fundamental statistics | |
|---|---|
| Market cap | US$889.08m |
| Earnings (TTM) | -US$205.75m |
| Revenue (TTM) | US$42.34m |
Is EYPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYPT income statement (TTM) | |
|---|---|
| Revenue | US$42.34m |
| Cost of Revenue | US$204.97m |
| Gross Profit | -US$162.63m |
| Other Expenses | US$43.13m |
| Earnings | -US$205.75m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | -384.10% |
| Net Profit Margin | -485.96% |
| Debt/Equity Ratio | 0% |
How did EYPT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 13:31 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EyePoint Pharmaceuticals, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jennifer Kim | Cantor Fitzgerald & Co. |